Used as a key intermediate in the synthesis of fluoroquinolone antibiotics, particularly in the production of advanced antimicrobial agents targeting resistant bacterial strains. Its structure supports enhanced penetration into bacterial cells and improves binding affinity to DNA gyrase and topoisomerase IV, making it valuable in developing drugs for treating urinary tract infections, respiratory infections, and other bacterial diseases. The compound’s chiral purity contributes to higher efficacy and reduced side effects in final pharmaceutical formulations.